Evidence map›Paper›PMID 36763374›Full record

ArticleThe oncologist2023

Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.

Surendra Pal Chaudhary, Stephanie Reyes, Matthew L Chase, Aparna Govindan, Lei Zhao, Jay Luther, Irun Bhan, Emily Bethea, Joseph W Franses, Elizabeth Paige Walsh and 21 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. NAFLD and NAFLD Related HCC: Emerging Treatments and Clinical Trials.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 7 institutions in 1 country.

Surendra Pal ChaudharyDivision of Oncology, Mass General Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-1541-8314
Stephanie ReyesDuke University School of Medicine, Durham, NC, USA.
Matthew L ChaseBeth Israel Deaconess Hospital, Needham, MA, USA.
Aparna GovindanIcahn School of Medicine at Mount Sinai, New York, NY, USA.
Lei ZhaoDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Jay LutherDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Irun BhanDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Emily BetheaDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Joseph W FransesDivision of Oncology, Mass General Cancer Center and Harvard Medical School, Boston, MA, USA.
Elizabeth Paige WalshDivision of Oncology, Mass General Cancer Center and Harvard Medical School, Boston, MA, USA.
Leigh Anne DagefordTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Shoko KimuraTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nahel EliasTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Heidi YehTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
James MarkmanTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Adel BozorgzadehTransplantation Unit, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Kenneth TanabeDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Cristina FerroneDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Andrew X ZhuJiahui Health, Jiahui International Cancer Center, Shanghai, People's Republic of China.
Karin AnderssonDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Michael ThiimDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Onofrio Antonio CatalanoDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Avinash KambadakoneDepartment of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Parsia A VagefiDivision of Surgical Transplantation, University of Texas Southwestern, Dallas, TX, USA.
Motaz QadanDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-6951-8308
Daniel PrattDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Nikroo HashemiDivision of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Kathleen E CoreyDivision of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Joseph MisdrajiDepartment of Pathology, Yale New Haven Hospital, Yale University, New Haven, CT, USA.
Lipika GoyalDivision of Oncology, Mass General Cancer Center and Harvard Medical School, Boston, MA, USA.
Jeffrey W ClarkDivision of Oncology, Mass General Cancer Center and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9524-3600
Harvard University · USBrigham and Women's Hospital · USBeth Israel Deaconess Hospital · USDuke University · USIcahn School of Medicine at Mount Sinai · USThe University of Texas Southwestern Medical Center · USYale New Haven Hospital · US

Funding

Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI SHIVDASANI, RAMESH A · 2007 to 2023
$33.2M
NCI NIH HHS P50 CA127003NCI NIH HHS SPORE P50 CA127003
6 · The paper itself

Abstract

backgroundNon-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the leading causes of hepatocellular carcinoma (HCC) worldwide. Limited data exist on surgical outcomes for NAFLD/NASH-related HCC compared with other HCC etiologies. We evaluated differences in clinicopathological characteristics and outcomes of patients undergoing surgical resection for NAFLD/NASH-associated HCC compared with other HCC etiologies.

methodsDemographic, clinicopathological features, and survival outcomes of patients with surgically resected HCC were collected. NAFLD activity score (NAS) and fibrosis score were assessed by focused pathologic review in a subset of patients.

resultsAmong 492 patients screened, 260 met eligibility (NAFLD/NASH [n = 110], and other etiologies [n = 150]). Median age at diagnosis was higher in the NAFLD/NASH HCC cohort compared with the other etiologies cohort (66.7 vs. 63.4 years, respectively, P = .005), with an increased percentage of female patients (36% vs. 18%, P = .001). NAFLD/NASH-related tumors were more commonly >5 cm (66.0% vs. 45%, P = .001). There were no significant differences in rates of lymphovascular or perineural invasion, histologic grade, or serum AFP levels. The NAFLD/NASH cohort had lower rates of background liver fibrosis, lower AST and ALT levels, and higher platelet counts (P < .01 for all). Median overall survival (OS) was numerically shorter in NAFLD/NASH vs other etiology groups, however, not statistically significant.

conclusionsPatients with NAFLD/NASH-related HCC more commonly lacked liver fibrosis and presented with larger HCCs compared with patients with HCC from other etiologies. No differences were seen in rates of other high-risk features or survival. With the caveat of sample size and retrospective analysis, this supports a similar decision-making approach regarding surgical resection for NAFLD/NASH and other etiology-related HCCs.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseFemaleHumansLiver CirrhosisRetrospective Studieshepatocellular carcinomametabolic syndromeNAFLDNASHoutcomesteatohepatitis

Identifiers

PMID36763374
PMCPMC10078904
OpenAlexW4319827626

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.